Literature DB >> 3157752

Induction of human T lymphocyte motility by interleukin 2.

H Kornfeld, J S Berman, D J Beer, D M Center.   

Abstract

Interleukin 2 (IL 2) is known to have multiple immunoenhancing activities that are related to its ability to promote the proliferation and the expression of effector functions of human T lymphocytes. We investigated the potential of IL 2 to induce human T lymphocyte migration. Unstimulated T cells did not respond to IL 2, but T cells exposed to dextran or phytohemagglutinin did respond to IL 2 concentrations from 0.01 to 10.0 U/ml, with significantly increased migration. This activity could be specifically blocked with anti-Tac antibody. Analysis of T lymphocyte subsets revealed that OKT4+ but not OKT8+ lymphocytes responded to IL 2 in the chemotaxis assay. Checkerboard analysis demonstrated that the IL 2-induced chemoattractant activity was predominantly chemotactic rather than chemokinetic in nature. The activity of IL 2 was compared with that of another chemoattractant lymphokine, lymphocyte chemoattractant factor, which was found to stimulate lymphocyte migration without prior exposure to mitogen, and which was not inhibited by anti-Tac. Our data suggest that the lymphocyte migratory response to IL 2 is under the control of the inducible receptor recognized by anti-Tac in a manner similar to the proliferative response to IL 2, but differs from proliferation in its OKT4+ cell specificity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157752

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Chemoattractant production by synovial fluid cells in chronic arthritis. A study with a new double-chamber method for quantitating the motility of mononuclear cells labelled with chromium-51.

Authors:  P J Nykänen; Y T Konttinen; V V Bergroth
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

2.  Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.

Authors:  Y Zaloom; L P Walsh; P McCulloch; G Gallagher
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

3.  Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen.

Authors:  J L Curtis; P K Byrd; M L Warnock; H B Kaltreider
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 4.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Authors:  Willem W Overwijk; Kimberly S Schluns
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

5.  Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors:  P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

6.  Staphylococcal enterotoxin B-specific adhesion of murine splenic T cells to a human endothelial cell line.

Authors:  M Kita; K Eguchi; Y Kawabe; T Tsukada; K Migita; A Kawakami; N Matsuoka; S Nagataki
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

7.  The bacterial superantigen Staphylococcal enterotoxin B stimulates lymphocyte locomotor capacity during culture in vitro.

Authors:  I Newman; P C Wilkinson
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

Review 8.  Interleukin-2 therapy for human cancer.

Authors:  Q G van Hoesel
Journal:  Lung       Date:  1990       Impact factor: 2.584

9.  Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.

Authors:  V F Tapson; M Boni-Schnetzler; P F Pilch; D M Center; J S Berman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

10.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.